-
Signature
-
Brett Sandercock, Chief Financial Officer
-
Stock symbol
-
RMD
-
Transactions as of
-
Jul 1, 2025
-
Transactions value $
-
-$704,864
-
Form type
-
4
-
Date filed
-
7/2/2025, 05:53 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Sandercock Brett |
Chief Financial Officer |
RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO |
Brett Sandercock, Chief Financial Officer |
2025-07-02 |
0001346064 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock |
Options Exercise |
$200K |
+1.97K |
+2.31% |
$101.64 |
87.2K |
Jul 1, 2025 |
Direct |
F1 |
| transaction |
RMD |
ResMed Common Stock |
Options Exercise |
$93.2K |
+917 |
+1.05% |
$101.64 |
88.2K |
Jul 1, 2025 |
Direct |
F1 |
| transaction |
RMD |
ResMed Common Stock |
Sale |
-$998K |
-3.88K |
-4.4% |
$256.99 |
84.3K |
Jul 1, 2025 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock Options |
Options Exercise |
$0 |
-1.97K |
-18.06% |
$0.00 |
8.92K |
Jul 1, 2025 |
ResMed Common Stock |
1.97K |
$101.64 |
Direct |
F1, F2 |
| transaction |
RMD |
ResMed Common Stock Options |
Options Exercise |
$0 |
-917 |
-10.28% |
$0.00 |
8K |
Jul 1, 2025 |
ResMed Common Stock |
917 |
$101.64 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: